

## **Perkins Coie Advises Pacira BioSciences, Inc. in \$402-Million Convertible Note Offering**

**DENVER (July 7, 2020)**—Perkins Coie represented New Jersey-based pharmaceuticals company, Pacira Biosciences, Inc., in its \$402-million offering of convertible senior notes in a [private placement](#) pursuant to Rule 144A under the Securities Act of 1933.

The Firmwide Chair of Perkins Coie's Corporate Practice, Jason Day, led the firm's deal team which also included Denver-based partner Ned Prusse and counsel Jonathan Schulman, Seattle-based partner Eric DeJong, and associates Christopher Wassman and Cassandra Wetzel.

Pacira BioSciences is a top provider of regenerative health treatments and non-opioid pain management committed to improving and advancing outcomes for healthcare practitioners and their patients.

Perkins Coie is a leading international law firm that is known for providing high-value, strategic solutions and extraordinary client service on matters vital to our clients' success. With more than 1,200 lawyers in offices across the United States and Asia, we provide a full array of corporate, commercial litigation, intellectual property, and regulatory legal advice to a broad range of clients, including many of the world's most innovative companies and industry leaders as well as public and not-for-profit organizations.

**Media Inquiries:** Please email [Justin Cole](#), Head of Media Relations.

### **Contact**



### **[Jason Day](#)**

Partner

[JDay@perkinscoie.com](mailto:JDay@perkinscoie.com) [303.291.2362](tel:303.291.2362)



**Ned A. Prusse**

Partner

[NPrusse@perkinscoie.com](mailto:NPrusse@perkinscoie.com) [303.291.2374](tel:303.291.2374)



**Jonathan S. Schulman**

Partner

[JSchulman@perkinscoie.com](mailto:JSchulman@perkinscoie.com) [303.291.2309](tel:303.291.2309)



**Eric A. DeJong**

Partner

[EDeJong@perkinscoie.com](mailto:EDeJong@perkinscoie.com) [206.359.3793](tel:206.359.3793)



## **Christopher Wassman**

Counsel

[CWassman@perkinscoie.com](mailto:CWassman@perkinscoie.com) [206.359.3807](tel:206.359.3807)

**Explore more in**

[Capital Markets](#)

**Media inquiries**